+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lemtrada"

Multiple Sclerosis Drugs Global Market Report 2024 - Product Thumbnail Image

Multiple Sclerosis Drugs Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
From
Multiple Sclerosis Forecast and Market Analysis to 2025 - Product Thumbnail Image

Multiple Sclerosis Forecast and Market Analysis to 2025

  • Report
  • July 2018
  • 765 Pages
  • Global
From
From
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Lemtrada is a brand name for alemtuzumab, a monoclonal antibody used to treat multiple sclerosis (MS). It is a type of central nervous system (CNS) drug, which are used to treat a variety of neurological conditions. Lemtrada is used to reduce the frequency of relapses in people with relapsing-remitting MS, and to slow the progression of disability. It is administered as an intravenous infusion over two or three days. The Lemtrada market is made up of pharmaceutical companies that produce and market the drug. These companies are involved in research and development, manufacturing, and marketing of the drug. They also provide support services to healthcare professionals and patients. Some companies in the Lemtrada market include Sanofi, Bayer, Biogen, Merck, and Novartis. Show Less Read more